Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Tysabri Could Return To Market As “Niche” Drug, Analyst Says

Aug 29 2005

• By Jessica Merrill

Related Content

Tysabri Withdrawal Prompts Biogen Idec To Suspend Financial Guidance

Apr 01 2005

Tysabri Could Return In Fall; Marketing Suspended By Biogen Idec And Elan

Feb 28 2005

Tysabri Safety Data To Be Submitted To FDA This Fall, Biogen Idec/Elan Say

Aug 09 2005

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window